BioXcel Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of BioXcel Therapeutics Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 14 Jan 2019 | Lorem |
| BioXcel’s Phase Ib/II BXCL701 has intriguing mechanism for neuroendocrine prostate cancer but carries blind spots; hard-to-treat tumour lowers efficacy expectations, experts say | 14 Jan 2019 | Reynald Castaneda |
| Tyme’s SM-88, BioXcel’s BXCL-701 have unclear Phase II success chances due to pancreatic cancer challenges, large data needed to excite, experts say | 25 Oct 2018 | Reynald Castaneda |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer